Form 4: Tonix CTO Siobhan Fogarty Receives Stock Option Grant

Tonix Pharmaceuticals' Chief Technology Officer, Siobhan Fogarty, was granted 78,023 stock options as part of her compensation package.

Summary

• Siobhan Fogarty, Chief Technology Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), was granted stock options on February 24, 2026.
• The grant includes two tranches of options: 39,012 options with an exercise price of $14.29 and 39,011 options with an exercise price of $17.8625.
• These options were granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.
• The options begin vesting one-third on the first anniversary of issuance (February 24, 2027), and then 1/48th each month thereafter for 36 months.
• All options have an expiration date of February 24, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Chief Technology Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• This compensation structure is a common practice for executive retention and motivation in publicly traded companies.

Future Outlook

The stock options are subject to a vesting schedule, with one-third vesting on the first anniversary of the grant date and the remainder vesting monthly over the subsequent 36 months, indicating a long-term incentive structure for the Chief Technology Officer.

Industry Context

StockSavvy.ai notes that the grant of stock options to a Chief Technology Officer is a standard practice within the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executive talent, aligning their performance with shareholder value creation.

Comparison to Industry Standards

• Not applicable for an individual insider transaction report, as this filing details a specific executive's compensation rather than company-wide performance metrics or project results.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Technology Officer's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This reflects the company's compensation strategy for key executives, which can influence overall employee morale and retention strategies.

Next Steps

• The stock options will begin to vest on February 24, 2027, and continue monthly thereafter for 36 months.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Stock Options, Executive Compensation, Insider Transaction, Form 4, Siobhan Fogarty, Chief Technology Officer, Equity Grant